AVTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Avalo Therapeutics Inc (AVTX) is not a strong buy for a beginner, long-term investor at this time. While there are positive catalysts such as hedge fund buying and upcoming clinical trial readouts, the lack of recent Intellectia Proprietary Trading Signals, poor financial performance, and neutral technical indicators suggest waiting for more clarity on the company's progress or a stronger entry point.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 51.028, and moving averages are converging, showing no clear trend. Key support is at 13.416, and resistance is at 17.48. The stock is trading closer to its support level, but there is no strong technical signal for a buy.
and are optimistic about the upcoming LOTUS Phase 2 trial, which could be a transformational catalyst.
The company's financial performance is poor, with revenue dropping 69.27% YoY and net income down 60.98% YoY. EPS has also fallen significantly by 78.20%. There is no recent news or congress trading data to support a positive sentiment.
In 2025/Q4, Avalo Therapeutics reported a revenue drop of 69.27% YoY to $59,000. Net income declined by 60.98% YoY to -$13.72M, and EPS dropped by 78.20% to -$0.75. However, gross margin increased to 100%, up 82.85% YoY.
Analysts are optimistic, with multiple 'Outperform' and 'Buy' ratings from Wolfe Research, Citizens, H.C. Wainwright, and Guggenheim. Price targets range from $40 to $52, and confidence in the upcoming Phase 2 LOTUS trial is high. However, analysts acknowledge the high-risk nature of the stock.
